NASDAQ:OPNT Opiant Pharmaceuticals (OPNT) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$20.03▼$21.1052-Week Range N/AVolume562,700 shsAverage Volume77,920 shsMarket Capitalization$108.83 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Opiant Pharmaceuticals alerts: Email Address Ad Golden CrestBiden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << About Opiant Pharmaceuticals Stock (NASDAQ:OPNT)Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Santa Monica, CA.Read More Ad Golden CrestBiden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << OPNT Stock News HeadlinesApril 18, 2024 | investing.comHikma Pharmaceuticals PLC ADR (HKMPY)January 31, 2024 | forbes.comIonis PharmaceuticalsSeptember 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… May 24, 2023 | msn.comUPDATE 2-US FDA approves Opiant's spray for reversing opioid-related overdosesMay 23, 2023 | msn.comREFILE-US FDA approves Opiant's overdose reversal sprayMarch 3, 2023 | msn.comIndivior Acquires Opiant Pharmaceuticals Strengthening Its Addiction Treatment And Science PortfolioFebruary 22, 2023 | finance.yahoo.comOpiant Pharmaceuticals, Inc.'s (NASDAQ:OPNT) largest shareholders are individual investors with 52% ownership, institutions own 33%February 7, 2023 | finance.yahoo.comOpiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLCSeptember 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… January 26, 2023 | seekingalpha.comHorizon Pharma, Opiant fall amid Elizabeth Warren concern about pharma deals (update)January 19, 2023 | finance.yahoo.comOpiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid OverdoseJanuary 14, 2023 | thetimes.co.ukDechra Pharmaceuticals defies cooling pets marketJanuary 13, 2023 | seekingalpha.comOpiant Pharmaceuticals: Nano-Cap Buyout With Interesting CVR Thrown InJanuary 7, 2023 | businesswire.comOPIANT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Opiant ...November 22, 2022 | finance.yahoo.comOpiant Pharmaceuticals Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid OverdoseNovember 15, 2022 | benzinga.comOPNT Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Sale of Opiant PharmaceuticalsNovember 15, 2022 | benzinga.comEQUITY ALERT: The M&A Class Action Firm Announces the Investigation of Opiant Pharmaceuticals, Inc. - OPNTNovember 14, 2022 | benzinga.comShareholder Alert: Ademi LLP investigates whether Opiant Pharmaceuticals Inc. has obtained a Fair Price in its transaction with IndiviorSee More Headlines Receive OPNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Opiant Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/11/2021Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:OPNT CUSIPN/A CIK1108924 Webwww.opiant.com Phone(310) 598-5410Fax917-322-2105Employees37Year Founded2009Profitability EPS (Most Recent Fiscal Year)($6.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$3.01 million Net Margins-147.90% Pretax Margin-147.84% Return on Equity-97.03% Return on Assets-59.66% Debt Debt-to-Equity Ratio0.60 Current Ratio5.48 Quick Ratio5.48 Sales & Book Value Annual Sales$47.78 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow24.75 Book Value$9.92 per share Price / BookN/AMiscellaneous Outstanding Shares5,270,000Free Float3,865,000Market Cap$108.83 million OptionableNot Optionable Beta0.84 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesRoger CrystalPresident, Chief Executive Officer & DirectorDavid D. O'TooleChief Financial Officer & SecretaryPhil SkolnickChief Scientific OfficerMark Jason H. EllisonChief Development OfficerMatthew R. RuthChief Commercial OfficerKey CompetitorsFoghorn TherapeuticsNASDAQ:FHTXSilverback TherapeuticsNASDAQ:SBTXCryoportNASDAQ:CYRXNeurogeneNASDAQ:NGNEKorro BioNASDAQ:KRROView All Competitors OPNT Stock Analysis - Frequently Asked Questions How were Opiant Pharmaceuticals' earnings last quarter? Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) released its quarterly earnings data on Thursday, November, 11th. The technology company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.15 by $0.41. The technology company had revenue of $16.34 million for the quarter, compared to analyst estimates of $12.45 million. Opiant Pharmaceuticals had a negative net margin of 147.90% and a negative trailing twelve-month return on equity of 97.03%. What other stocks do shareholders of Opiant Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Opiant Pharmaceuticals investors own include Cara Therapeutics (CARA), AcelRx Pharmaceuticals (ACRX), Sangamo Therapeutics (SGMO), Synchrony Financial (SYF), Vodafone Group Public (VOD), Agenus (AGEN) and Aldeyra Therapeutics (ALDX). This page (NASDAQ:OPNT) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opiant Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Opiant Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OPNT Stock Alerts